CD4 and neoplasm: At 2 weeks after tumour implantation, CD8+, but not CD4+, T cells in tumours treated with MJ18 were significantly more than that in controls, as indicated by real-time PCR (CD8+ T cells, n=3, P=0.024; CD4+ T cells, n=3, N.S.; controls, n=4) (Figure 5A).